Build a Business FOR BETTER Vision
A Growing Integrative Eye-Care Model for Entrepreneurs and Healthcare Professionals
Millions of people around the world living with chronic and degenerative eye conditions and are actively searching for care beyond what conventional treatment alone offers.
Netra Eye Institute meets this growing demand through Netra Restoration Therapy (NRT), a structured program that combines acupuncture, herbal medicine, Ayurveda, and lifestyle guidance to support retinal and optic nerve health. Franchise owners operate a specialized clinic with a clear treatment model, ongoing patient care, and services that attract patients from both nearby and distant areas.
Read more about the Netra franchise →DESTINATION FOR INTEGRATIVE EYE CARE
A Mission With Meaning
Vision affects nearly every part of daily life. It shapes how people read, work, drive, move safely, recognize faces, maintain independence, and participate in their communities.
Owning a Netra Eye Institute is more than opening another health-and-wellness business. It is an opportunity to create a trusted destination for patients who are looking for a coordinated, science-aware, complementary approach to protecting and supporting their vision.
Global eye disease burden
A Worldwide Need for Vision Care
From glaucoma and diabetic retinopathy to myopia and macular degeneration, major eye conditions affect hundreds of millions of people across every region. Hover over a market to see the modeled burden by condition.
Country Selection
Clear all
Austria
aut
Sweden
swe
Romania
rou
Ukraine
ukr
Greece
grc
Belgium
bel
Portugal
prt
Malaysia
mys
Taiwan
twn
Morocco
mar
Yemen
yem
Sudan
sdn
Iraq
irq
Netherlands
nld
Colombia
col
Poland
pol
Argentina
arg
Philippines
phl
Thailand
tha
Vietnam
vnm
Bangladesh
bgd
Egypt
egy
Iran
irn
Switzerland
che
Pakistan
pak
Singapore
sgp
Australia
aus
Indonesia
idn
South Korea
kor
Japan
jpn
India
ind
China
chn
South Africa
zaf
Nigeria
nga
Saudi Arabia
sau
Turkey
tur
Russia
rus
Spain
esp
Italy
ita
Germany
deu
France
fra
United Kingdom
gbr
Brazil
bra
Mexico
mex
Canada
can
United States
usa
aut
54
26
Austria
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 128,074 | 8,872 |
|---|---|---|
| Normal-tension | 43,545 | — |
Diabetic retinopathy
| NPDR | 82,670 | 20,287 |
|---|---|---|
| PDR | 44,124 | 4,129 |
Age-related macular degeneration
| Dry | 843,750 | 72,305 |
|---|---|---|
| Wet | 93,750 | 6,958 |
Myopia
| Myopia | 2.74 million | 31,951 |
|---|---|---|
| High myopia | 410,259 | 4,793 |
Uveitis (non-infectious)
| All | 11,998 | 3,191 |
|---|
Keratoconus
| All cases | 18,450 | 255 |
|---|
Corneal neuralgia
| All cases | 1,823 | 182 |
|---|
Inherited retinal disease
| Combined | 4,413 | 67 |
|---|
swe
54
16
Sweden
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 136,943 | 9,421 |
|---|---|---|
| Normal-tension | 46,561 | — |
Diabetic retinopathy
| NPDR | 96,417 | 23,661 |
|---|---|---|
| PDR | 51,462 | 4,816 |
Age-related macular degeneration
| Dry | 902,182 | 76,781 |
|---|---|---|
| Wet | 100,242 | 7,388 |
Myopia
| Myopia | 3.19 million | 41,242 |
|---|---|---|
| High myopia | 478,481 | 6,186 |
Uveitis (non-infectious)
| All | 13,993 | 3,722 |
|---|
Keratoconus
| All cases | 21,518 | 298 |
|---|
Corneal neuralgia
| All cases | 2,127 | 213 |
|---|
Inherited retinal disease
| Combined | 5,147 | 79 |
|---|
rou
57
27
Romania
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 251,197 | 18,782 |
|---|---|---|
| Normal-tension | 85,407 | — |
Diabetic retinopathy
| NPDR | 171,946 | 42,195 |
|---|---|---|
| PDR | 91,775 | 8,588 |
Age-related macular degeneration
| Dry | 1.16 million | 153,069 |
|---|---|---|
| Wet | 128,738 | 14,729 |
Myopia
| Myopia | 5.12 million | 63,718 |
|---|---|---|
| High myopia | 758,494 | 9,558 |
Uveitis (non-infectious)
| All | 24,954 | 6,637 |
|---|
Keratoconus
| All cases | 38,374 | 531 |
|---|
Corneal neuralgia
| All cases | 3,792 | 379 |
|---|
Inherited retinal disease
| Combined | 9,178 | 143 |
|---|
ukr
59
25
Ukraine
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 569,569 | 37,739 |
|---|---|---|
| Normal-tension | 193,653 | — |
Diabetic retinopathy
| NPDR | 347,106 | 85,179 |
|---|---|---|
| PDR | 185,265 | 17,336 |
Age-related macular degeneration
| Dry | 2.34 million | 307,563 |
|---|---|---|
| Wet | 259,470 | 29,596 |
Myopia
| Myopia | 9.57 million | 120,288 |
|---|---|---|
| High myopia | 1.34 million | 18,043 |
Uveitis (non-infectious)
| All | 50,375 | 13,398 |
|---|
Keratoconus
| All cases | 77,466 | 1,072 |
|---|
Corneal neuralgia
| All cases | 7,656 | 766 |
|---|
Inherited retinal disease
| Combined | 18,528 | 284 |
|---|
grc
56
32
Greece
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 151,888 | 10,384 |
|---|---|---|
| Normal-tension | 51,642 | — |
Diabetic retinopathy
| NPDR | 90,307 | 22,161 |
|---|---|---|
| PDR | 48,201 | 4,510 |
Age-related macular degeneration
| Dry | 1 million | 84,623 |
|---|---|---|
| Wet | 111,182 | 8,143 |
Myopia
| Myopia | 2.99 million | 31,069 |
|---|---|---|
| High myopia | 448,160 | 4,660 |
Uveitis (non-infectious)
| All | 13,106 | 3,486 |
|---|
Keratoconus
| All cases | 20,154 | 279 |
|---|
Corneal neuralgia
| All cases | 1,992 | 199 |
|---|
Inherited retinal disease
| Combined | 4,821 | 75 |
|---|
bel
51
24
Belgium
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 157,492 | 10,981 |
|---|---|---|
| Normal-tension | 53,547 | — |
Diabetic retinopathy
| NPDR | 106,545 | 26,146 |
|---|---|---|
| PDR | 56,867 | 5,321 |
Age-related macular degeneration
| Dry | 1.04 million | 89,491 |
|---|---|---|
| Wet | 115,284 | 8,611 |
Myopia
| Myopia | 3.52 million | 43,601 |
|---|---|---|
| High myopia | 528,743 | 6,540 |
Uveitis (non-infectious)
| All | 15,463 | 4,112 |
|---|
Keratoconus
| All cases | 23,778 | 329 |
|---|
Corneal neuralgia
| All cases | 2,350 | 235 |
|---|
Inherited retinal disease
| Combined | 5,685 | 87 |
|---|
prt
48
32
Portugal
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 157,913 | 10,861 |
|---|---|---|
| Normal-tension | 53,690 | — |
Diabetic retinopathy
| NPDR | 94,485 | 23,187 |
|---|---|---|
| PDR | 50,431 | 4,719 |
Age-related macular degeneration
| Dry | 1.04 million | 88,512 |
|---|---|---|
| Wet | 115,592 | 8,517 |
Myopia
| Myopia | 3.13 million | 32,827 |
|---|---|---|
| High myopia | 468,897 | 4,924 |
Uveitis (non-infectious)
| All | 13,713 | 3,647 |
|---|
Keratoconus
| All cases | 21,087 | 292 |
|---|
Corneal neuralgia
| All cases | 2,084 | 208 |
|---|
Inherited retinal disease
| Combined | 5,043 | 78 |
|---|
mys
78
58
Malaysia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 317,810 | 27,558 |
|---|---|---|
| Normal-tension | 238,358 | — |
Diabetic retinopathy
| NPDR | 604,975 | 122,860 |
|---|---|---|
| PDR | 275,024 | 25,735 |
Age-related macular degeneration
| Dry | 789,440 | 195,180 |
|---|---|---|
| Wet | 87,716 | 18,781 |
Myopia
| Myopia | 13.6 million | 415,057 |
|---|---|---|
| High myopia | 2.15 million | 62,258 |
Uveitis (non-infectious)
| All | 47,075 | 12,520 |
|---|
Keratoconus
| All cases | 124,097 | 1,717 |
|---|
Corneal neuralgia
| All cases | 7,154 | 715 |
|---|
Inherited retinal disease
| Combined | 17,314 | 268 |
|---|
twn
84
43
Taiwan
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 315,596 | 28,668 |
|---|---|---|
| Normal-tension | 258,788 | — |
Diabetic retinopathy
| NPDR | 391,752 | 79,558 |
|---|---|---|
| PDR | 178,093 | 16,665 |
Age-related macular degeneration
| Dry | 852,108 | 203,039 |
|---|---|---|
| Wet | 94,679 | 19,538 |
Myopia
| Myopia | 12.7 million | 236,052 |
|---|---|---|
| High myopia | 2.32 million | 35,408 |
Uveitis (non-infectious)
| All | 30,483 | 8,107 |
|---|
Keratoconus
| All cases | 33,483 | 463 |
|---|
Corneal neuralgia
| All cases | 4,633 | 463 |
|---|
Inherited retinal disease
| Combined | 11,211 | 173 |
|---|
mar
48
37
Morocco
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 508,742 | 34,153 |
|---|---|---|
| Normal-tension | 239,109 | — |
Diabetic retinopathy
| NPDR | 702,820 | 116,877 |
|---|---|---|
| PDR | 271,155 | 25,373 |
Age-related macular degeneration
| Dry | 989,985 | 211,955 |
|---|---|---|
| Wet | 109,998 | 20,396 |
Myopia
| Myopia | 9.57 million | 196,090 |
|---|---|---|
| High myopia | 1.34 million | 29,414 |
Uveitis (non-infectious)
| All | 50,352 | 13,391 |
|---|
Keratoconus
| All cases | 221,225 | 3,061 |
|---|
Corneal neuralgia
| All cases | 7,652 | 765 |
|---|
Inherited retinal disease
| Combined | 18,518 | 284 |
|---|
yem
63
49
Yemen
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 271,340 | 18,416 |
|---|---|---|
| Normal-tension | 127,530 | — |
Diabetic retinopathy
| NPDR | 756,422 | 125,791 |
|---|---|---|
| PDR | 291,834 | 27,308 |
Age-related macular degeneration
| Dry | 528,014 | 114,291 |
|---|---|---|
| Wet | 58,668 | 10,998 |
Myopia
| Myopia | 10.3 million | 270,764 |
|---|---|---|
| High myopia | 1.44 million | 40,615 |
Uveitis (non-infectious)
| All | 54,192 | 14,413 |
|---|
Keratoconus
| All cases | 238,097 | 3,294 |
|---|
Corneal neuralgia
| All cases | 8,236 | 824 |
|---|
Inherited retinal disease
| Combined | 19,931 | 307 |
|---|
sdn
58
49
Sudan
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 421,530 | 24,080 |
|---|---|---|
| Normal-tension | 223,411 | — |
Diabetic retinopathy
| NPDR | 934,056 | 155,331 |
|---|---|---|
| PDR | 360,367 | 33,721 |
Age-related macular degeneration
| Dry | 646,666 | 149,441 |
|---|---|---|
| Wet | 71,852 | 14,380 |
Myopia
| Myopia | 6.1 million | 144,442 |
|---|---|---|
| High myopia | 762,740 | 21,666 |
Uveitis (non-infectious)
| All | 66,918 | 17,797 |
|---|
Keratoconus
| All cases | 294,011 | 4,068 |
|---|
Corneal neuralgia
| All cases | 10,170 | 1,017 |
|---|
Inherited retinal disease
| Combined | 24,609 | 379 |
|---|
irq
62
36
Iraq
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 382,067 | 25,922 |
|---|---|---|
| Normal-tension | 179,572 | — |
Diabetic retinopathy
| NPDR | 854,642 | 142,125 |
|---|---|---|
| PDR | 329,729 | 30,854 |
Age-related macular degeneration
| Dry | 743,482 | 160,873 |
|---|---|---|
| Wet | 82,609 | 15,480 |
Myopia
| Myopia | 11.6 million | 289,600 |
|---|---|---|
| High myopia | 1.63 million | 43,440 |
Uveitis (non-infectious)
| All | 61,228 | 16,284 |
|---|
Keratoconus
| All cases | 269,014 | 3,722 |
|---|
Corneal neuralgia
| All cases | 9,305 | 931 |
|---|
Inherited retinal disease
| Combined | 22,520 | 346 |
|---|
nld
52
23
Netherlands
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 242,124 | 17,070 |
|---|---|---|
| Normal-tension | 94,186 | — |
Diabetic retinopathy
| NPDR | 165,867 | 40,704 |
|---|---|---|
| PDR | 88,530 | 8,284 |
Age-related macular degeneration
| Dry | 1.6 million | 139,112 |
|---|---|---|
| Wet | 177,235 | 13,386 |
Myopia
| Myopia | 5.49 million | 68,856 |
|---|---|---|
| High myopia | 823,137 | 10,328 |
Uveitis (non-infectious)
| All | 24,072 | 6,402 |
|---|
Keratoconus
| All cases | 37,017 | 512 |
|---|
Corneal neuralgia
| All cases | 3,658 | 366 |
|---|
Inherited retinal disease
| Combined | 8,855 | 136 |
|---|
col
29
57
Colombia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 650,323 | 42,314 |
|---|---|---|
| Normal-tension | 260,129 | — |
Diabetic retinopathy
| NPDR | 194,710 | 105,259 |
|---|---|---|
| PDR | 211,416 | 19,783 |
Age-related macular degeneration
| Dry | 1.89 million | 319,921 |
|---|---|---|
| Wet | 209,782 | 30,785 |
Myopia
| Myopia | 13.29 million | 225,294 |
|---|---|---|
| High myopia | 1.86 million | 33,794 |
Uveitis (non-infectious)
| All | 69,963 | 18,607 |
|---|
Keratoconus
| All cases | 138,325 | 1,914 |
|---|
Corneal neuralgia
| All cases | 10,633 | 1,063 |
|---|
Inherited retinal disease
| Combined | 25,731 | 396 |
|---|
pol
55
23
Poland
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 510,219 | 38,266 |
|---|---|---|
| Normal-tension | 173,475 | — |
Diabetic retinopathy
| NPDR | 347,900 | 85,374 |
|---|---|---|
| PDR | 185,689 | 17,376 |
Age-related macular degeneration
| Dry | 2.35 million | 311,856 |
|---|---|---|
| Wet | 261,487 | 30,009 |
Myopia
| Myopia | 10.36 million | 128,306 |
|---|---|---|
| High myopia | 1.53 million | 19,246 |
Uveitis (non-infectious)
| All | 50,491 | 13,428 |
|---|
Keratoconus
| All cases | 77,643 | 1,074 |
|---|
Corneal neuralgia
| All cases | 7,673 | 767 |
|---|
Inherited retinal disease
| Combined | 18,569 | 287 |
|---|
arg
32
87
Argentina
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 618,172 | 36,556 |
|---|---|---|
| Normal-tension | 247,269 | — |
Diabetic retinopathy
| NPDR | 167,649 | 90,630 |
|---|---|---|
| PDR | 182,034 | 17,034 |
Age-related macular degeneration
| Dry | 1.69 million | 276,386 |
|---|---|---|
| Wet | 187,325 | 26,596 |
Myopia
| Myopia | 12.82 million | 202,815 |
|---|---|---|
| High myopia | 1.83 million | 30,422 |
Uveitis (non-infectious)
| All | 60,239 | 16,021 |
|---|
Keratoconus
| All cases | 119,101 | 1,648 |
|---|
Corneal neuralgia
| All cases | 9,155 | 915 |
|---|
Inherited retinal disease
| Combined | 22,155 | 340 |
|---|
phl
84
51
Philippines
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 852,560 | 75,072 |
|---|---|---|
| Normal-tension | 639,420 | — |
Diabetic retinopathy
| NPDR | 1.97 million | 399,502 |
|---|---|---|
| PDR | 894,292 | 83,683 |
Age-related macular degeneration
| Dry | 2.12 million | 531,689 |
|---|---|---|
| Wet | 235,307 | 51,163 |
Myopia
| Myopia | 44.2 million | 1.48 million |
|---|---|---|
| High myopia | 6.98 million | 221,977 |
Uveitis (non-infectious)
| All | 153,072 | 40,711 |
|---|
Keratoconus
| All cases | 403,524 | 5,583 |
|---|
Corneal neuralgia
| All cases | 23,263 | 2,326 |
|---|
Inherited retinal disease
| Combined | 56,297 | 865 |
|---|
tha
78
49
Thailand
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 929,830 | 91,465 |
|---|---|---|
| Normal-tension | 697,372 | — |
Diabetic retinopathy
| NPDR | 541,912 | 112,418 |
|---|---|---|
| PDR | 250,778 | 23,467 |
Age-related macular degeneration
| Dry | 2.31 million | 553,597 |
|---|---|---|
| Wet | 256,633 | 53,271 |
Myopia
| Myopia | 27.23 million | 620,165 |
|---|---|---|
| High myopia | 4.3 million | 93,025 |
Uveitis (non-infectious)
| All | 94,287 | 25,076 |
|---|
Keratoconus
| All cases | 248,557 | 3,439 |
|---|
Corneal neuralgia
| All cases | 14,329 | 1,433 |
|---|
Inherited retinal disease
| Combined | 34,677 | 533 |
|---|
vnm
79
49
Vietnam
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.02 million | 87,705 |
|---|---|---|
| Normal-tension | 761,353 | — |
Diabetic retinopathy
| NPDR | 1.71 million | 347,927 |
|---|---|---|
| PDR | 778,841 | 72,880 |
Age-related macular degeneration
| Dry | 2.52 million | 621,161 |
|---|---|---|
| Wet | 280,178 | 59,772 |
Myopia
| Myopia | 38.49 million | 1.09 million |
|---|---|---|
| High myopia | 6.08 million | 163,875 |
Uveitis (non-infectious)
| All | 133,311 | 35,455 |
|---|
Keratoconus
| All cases | 351,430 | 4,862 |
|---|
Corneal neuralgia
| All cases | 20,260 | 2,026 |
|---|
Inherited retinal disease
| Combined | 49,029 | 755 |
|---|
bgd
75
43
Bangladesh
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.24 million | 130,945 |
|---|---|---|
| Normal-tension | 1.03 million | — |
Diabetic retinopathy
| NPDR | 1.32 million | 273,984 |
|---|---|---|
| PDR | 611,196 | 57,192 |
Age-related macular degeneration
| Dry | 3.22 million | 792,547 |
|---|---|---|
| Wet | 357,409 | 76,264 |
Myopia
| Myopia | 52.39 million | 1.47 million |
|---|---|---|
| High myopia | 6.98 million | 221,074 |
Uveitis (non-infectious)
| All | 229,796 | 61,116 |
|---|
Keratoconus
| All cases | 1.51 million | 20,954 |
|---|
Corneal neuralgia
| All cases | 34,923 | 3,492 |
|---|
Inherited retinal disease
| Combined | 84,515 | 1,300 |
|---|
egy
59
41
Egypt
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.23 million | 83,802 |
|---|---|---|
| Normal-tension | 578,458 | — |
Diabetic retinopathy
| NPDR | 2.16 million | 358,924 |
|---|---|---|
| PDR | 832,705 | 77,920 |
Age-related macular degeneration
| Dry | 2.39 million | 520,085 |
|---|---|---|
| Wet | 266,110 | 50,046 |
Myopia
| Myopia | 29.37 million | 673,874 |
|---|---|---|
| High myopia | 4.11 million | 101,081 |
Uveitis (non-infectious)
| All | 154,628 | 41,124 |
|---|
Keratoconus
| All cases | 679,374 | 9,400 |
|---|
Corneal neuralgia
| All cases | 23,500 | 2,350 |
|---|
Inherited retinal disease
| Combined | 56,870 | 873 |
|---|
irn
65
37
Iran
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.35 million | 90,353 |
|---|---|---|
| Normal-tension | 631,190 | — |
Diabetic retinopathy
| NPDR | 1.69 million | 281,098 |
|---|---|---|
| PDR | 652,147 | 61,024 |
Age-related macular degeneration
| Dry | 2.62 million | 560,739 |
|---|---|---|
| Wet | 290,988 | 53,958 |
Myopia
| Myopia | 23.01 million | 445,177 |
|---|---|---|
| High myopia | 3.22 million | 66,777 |
Uveitis (non-infectious)
| All | 121,099 | 32,207 |
|---|
Keratoconus
| All cases | 532,064 | 7,362 |
|---|
Corneal neuralgia
| All cases | 18,404 | 1,840 |
|---|
Inherited retinal disease
| Combined | 44,537 | 685 |
|---|
che
52
27
Switzerland
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 123,886 | 8,629 |
|---|---|---|
| Normal-tension | 42,121 | — |
Diabetic retinopathy
| NPDR | 81,119 | 19,907 |
|---|---|---|
| PDR | 43,297 | 4,051 |
Age-related macular degeneration
| Dry | 816,159 | 70,325 |
|---|---|---|
| Wet | 90,684 | 6,767 |
Myopia
| Myopia | 2.68 million | 31,924 |
|---|---|---|
| High myopia | 402,565 | 4,789 |
Uveitis (non-infectious)
| All | 11,773 | 3,131 |
|---|
Keratoconus
| All cases | 18,104 | 250 |
|---|
Corneal neuralgia
| All cases | 1,789 | 179 |
|---|
Inherited retinal disease
| Combined | 4,329 | 66 |
|---|
pak
69
39
Pakistan
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.36 million | 141,494 |
|---|---|---|
| Normal-tension | 1.02 million | — |
Diabetic retinopathy
| NPDR | 4.65 million | 773,465 |
|---|---|---|
| PDR | 1.79 million | 167,914 |
Age-related macular degeneration
| Dry | 3.52 million | 878,124 |
|---|---|---|
| Wet | 390,784 | 84,499 |
Myopia
| Myopia | 75.96 million | 2.36 million |
|---|---|---|
| High myopia | 10.13 million | 353,821 |
Uveitis (non-infectious)
| All | 333,215 | 88,621 |
|---|
Keratoconus
| All cases | 2.2 million | 30,384 |
|---|
Corneal neuralgia
| All cases | 50,641 | 5,064 |
|---|
Inherited retinal disease
| Combined | 122,550 | 1,886 |
|---|
sgp
79
59
Singapore
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 89,572 | 5,552 |
|---|---|---|
| Normal-tension | 75,778 | — |
Diabetic retinopathy
| NPDR | 98,977 | 20,100 |
|---|---|---|
| PDR | 44,995 | 4,210 |
Age-related macular degeneration
| Dry | 163,601 | 39,320 |
|---|---|---|
| Wet | 18,178 | 3,784 |
Myopia
| Myopia | 2.63 million | 64,357 |
|---|---|---|
| High myopia | 468,185 | 9,653 |
Uveitis (non-infectious)
| All | 7,702 | 2,048 |
|---|
Keratoconus
| All cases | 16,919 | 234 |
|---|
Corneal neuralgia
| All cases | 1,170 | 117 |
|---|
Inherited retinal disease
| Combined | 2,833 | 45 |
|---|
aus
87
78
Australia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 327,168 | 26,615 |
|---|---|---|
| Normal-tension | 114,509 | — |
Diabetic retinopathy
| NPDR | 454,012 | 92,202 |
|---|---|---|
| PDR | 206,396 | 19,313 |
Age-related macular degeneration
| Dry | 1.18 million | 188,498 |
|---|---|---|
| Wet | 130,867 | 18,138 |
Myopia
| Myopia | 8.59 million | 116,945 |
|---|---|---|
| High myopia | 1.34 million | 17,542 |
Uveitis (non-infectious)
| All | 35,328 | 9,396 |
|---|
Keratoconus
| All cases | 77,609 | 1,074 |
|---|
Corneal neuralgia
| All cases | 5,369 | 537 |
|---|
Inherited retinal disease
| Combined | 12,992 | 200 |
|---|
idn
80
65
Indonesia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 2.64 million | 269,830 |
|---|---|---|
| Normal-tension | 1.98 million | — |
Diabetic retinopathy
| NPDR | 2.15 million | 446,588 |
|---|---|---|
| PDR | 996,235 | 93,222 |
Age-related macular degeneration
| Dry | 6.57 million | 1.63 million |
|---|---|---|
| Wet | 729,778 | 157,153 |
Myopia
| Myopia | 108.16 million | 3.22 million |
|---|---|---|
| High myopia | 17.08 million | 482,915 |
Uveitis (non-infectious)
| All | 374,563 | 99,618 |
|---|
Keratoconus
| All cases | 987,411 | 13,662 |
|---|
Corneal neuralgia
| All cases | 56,924 | 5,692 |
|---|
Inherited retinal disease
| Combined | 137,757 | 2,120 |
|---|
kor
86
34
South Korea
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.05 million | 63,657 |
|---|---|---|
| Normal-tension | 807,536 | — |
Diabetic retinopathy
| NPDR | 874,321 | 177,560 |
|---|---|---|
| PDR | 397,471 | 37,193 |
Age-related macular degeneration
| Dry | 1.92 million | 450,845 |
|---|---|---|
| Wet | 212,834 | 43,383 |
Myopia
| Myopia | 23.26 million | 417,031 |
|---|---|---|
| High myopia | 4.14 million | 62,555 |
Uveitis (non-infectious)
| All | 68,033 | 18,094 |
|---|
Keratoconus
| All cases | 149,456 | 2,068 |
|---|
Corneal neuralgia
| All cases | 10,339 | 1,034 |
|---|
Inherited retinal disease
| Combined | 25,022 | 386 |
|---|
jpn
89
34
Japan
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 2.68 million | 147,709 |
|---|---|---|
| Normal-tension | 2.48 million | — |
Diabetic retinopathy
| NPDR | 2.09 million | 423,952 |
|---|---|---|
| PDR | 949,024 | 88,805 |
Age-related macular degeneration
| Dry | 4.9 million | 1.05 million |
|---|---|---|
| Wet | 544,544 | 100,665 |
Myopia
| Myopia | 55.55 million | 890,310 |
|---|---|---|
| High myopia | 9.87 million | 133,546 |
Uveitis (non-infectious)
| All | 162,440 | 43,202 |
|---|
Keratoconus
| All cases | 356,850 | 4,937 |
|---|
Corneal neuralgia
| All cases | 24,687 | 2,469 |
|---|
Inherited retinal disease
| Combined | 59,743 | 920 |
|---|
ind
72
44
India
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 11.71 million | 1.24 million |
|---|---|---|
| Normal-tension | 9.61 million | — |
Diabetic retinopathy
| NPDR | 11.02 million | 2.29 million |
|---|---|---|
| PDR | 5.1 million | 477,354 |
Age-related macular degeneration
| Dry | 30.31 million | 7.51 million |
|---|---|---|
| Wet | 3.37 million | 722,491 |
Myopia
| Myopia | 437.23 million | 11.63 million |
|---|---|---|
| High myopia | 58.3 million | 1.74 million |
Uveitis (non-infectious)
| All | 1.92 million | 510,102 |
|---|
Keratoconus
| All cases | 12.64 million | 174,892 |
|---|
Corneal neuralgia
| All cases | 291,487 | 29,149 |
|---|
Inherited retinal disease
| Combined | 705,399 | 10,852 |
|---|
chn
79
35
China
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 16.7 million | 1.55 million |
|---|---|---|
| Normal-tension | 13.6 million | — |
Diabetic retinopathy
| NPDR | 23.98 million | 4.87 million |
|---|---|---|
| PDR | 10.9 million | 1.02 million |
Age-related macular degeneration
| Dry | 45.1 million | 10.97 million |
|---|---|---|
| Wet | 5.01 million | 1.06 million |
Myopia
| Myopia | 779.75 million | 17.29 million |
|---|---|---|
| High myopia | 141.77 million | 2.59 million |
Uveitis (non-infectious)
| All | 1.87 million | 496,207 |
|---|
Keratoconus
| All cases | 2.05 million | 28,355 |
|---|
Corneal neuralgia
| All cases | 283,547 | 28,355 |
|---|
Inherited retinal disease
| Combined | 686,184 | 10,557 |
|---|
zaf
57
81
South Africa
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 822,646 | 57,636 |
|---|---|---|
| Normal-tension | 469,731 | — |
Diabetic retinopathy
| NPDR | 356,869 | 31,618 |
|---|---|---|
| PDR | 85,826 | 8,031 |
Age-related macular degeneration
| Dry | 1.39 million | 315,137 |
|---|---|---|
| Wet | 154,246 | 30,324 |
Myopia
| Myopia | 9.66 million | 197,192 |
|---|---|---|
| High myopia | 1.29 million | 29,579 |
Uveitis (non-infectious)
| All | 84,733 | 22,535 |
|---|
Keratoconus
| All cases | 372,283 | 5,151 |
|---|
Corneal neuralgia
| All cases | 12,877 | 1,288 |
|---|
Inherited retinal disease
| Combined | 31,163 | 481 |
|---|
nga
52
53
Nigeria
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 2.19 million | 127,658 |
|---|---|---|
| Normal-tension | 1.16 million | — |
Diabetic retinopathy
| NPDR | 1.3 million | 115,442 |
|---|---|---|
| PDR | 313,369 | 29,323 |
Age-related macular degeneration
| Dry | 3.02 million | 697,994 |
|---|---|---|
| Wet | 335,234 | 67,165 |
Myopia
| Myopia | 23.51 million | 571,170 |
|---|---|---|
| High myopia | 2.82 million | 85,675 |
Uveitis (non-infectious)
| All | 309,376 | 82,281 |
|---|
Keratoconus
| All cases | 1.36 million | 18,807 |
|---|
Corneal neuralgia
| All cases | 47,018 | 4,702 |
|---|
Inherited retinal disease
| Combined | 113,782 | 1,751 |
|---|
sau
62
43
Saudi Arabia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 361,962 | 24,677 |
|---|---|---|
| Normal-tension | 170,122 | — |
Diabetic retinopathy
| NPDR | 629,403 | 104,668 |
|---|---|---|
| PDR | 242,830 | 22,723 |
Age-related macular degeneration
| Dry | 704,359 | 153,150 |
|---|---|---|
| Wet | 78,262 | 14,737 |
Myopia
| Myopia | 8.57 million | 195,852 |
|---|---|---|
| High myopia | 1.2 million | 29,378 |
Uveitis (non-infectious)
| All | 45,092 | 11,992 |
|---|
Keratoconus
| All cases | 198,116 | 2,741 |
|---|
Corneal neuralgia
| All cases | 6,853 | 685 |
|---|
Inherited retinal disease
| Combined | 16,583 | 256 |
|---|
tur
60
32
Turkey
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.34 million | 67,690 |
|---|---|---|
| Normal-tension | 631,531 | — |
Diabetic retinopathy
| NPDR | 794,118 | 194,875 |
|---|---|---|
| PDR | 423,854 | 39,662 |
Age-related macular degeneration
| Dry | 2.61 million | 551,654 |
|---|---|---|
| Wet | 290,526 | 53,084 |
Myopia
| Myopia | 21.89 million | 410,081 |
|---|---|---|
| High myopia | 3.07 million | 61,512 |
Uveitis (non-infectious)
| All | 115,250 | 30,652 |
|---|
Keratoconus
| All cases | 506,364 | 7,006 |
|---|
Corneal neuralgia
| All cases | 17,515 | 1,752 |
|---|
Inherited retinal disease
| Combined | 42,388 | 651 |
|---|
rus
72
18
Russia
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 2.02 million | 136,578 |
|---|---|---|
| Normal-tension | 687,535 | — |
Diabetic retinopathy
| NPDR | 1.31 million | 321,400 |
|---|---|---|
| PDR | 699,045 | 65,413 |
Age-related macular degeneration
| Dry | 8.29 million | 1.11 million |
|---|---|---|
| Wet | 921,208 | 107,106 |
Myopia
| Myopia | 36.11 million | 486,782 |
|---|---|---|
| High myopia | 5.06 million | 73,017 |
Uveitis (non-infectious)
| All | 190,077 | 50,552 |
|---|
Keratoconus
| All cases | 292,294 | 4,044 |
|---|
Corneal neuralgia
| All cases | 28,887 | 2,889 |
|---|
Inherited retinal disease
| Combined | 69,907 | 1,075 |
|---|
esp
49
31
Spain
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 715,868 | 49,882 |
|---|---|---|
| Normal-tension | 243,395 | — |
Diabetic retinopathy
| NPDR | 434,393 | 106,600 |
|---|---|---|
| PDR | 231,854 | 21,696 |
Age-related macular degeneration
| Dry | 4.72 million | 406,523 |
|---|---|---|
| Wet | 524,015 | 39,118 |
Myopia
| Myopia | 14.37 million | 154,164 |
|---|---|---|
| High myopia | 2.16 million | 23,125 |
Uveitis (non-infectious)
| All | 63,043 | 16,767 |
|---|
Keratoconus
| All cases | 96,946 | 1,341 |
|---|
Corneal neuralgia
| All cases | 9,581 | 958 |
|---|
Inherited retinal disease
| Combined | 23,185 | 357 |
|---|
ita
54
30
Italy
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 915,310 | 62,354 |
|---|---|---|
| Normal-tension | 274,593 | — |
Diabetic retinopathy
| NPDR | 537,270 | 131,845 |
|---|---|---|
| PDR | 286,764 | 26,834 |
Age-related macular degeneration
| Dry | 6.03 million | 508,166 |
|---|---|---|
| Wet | 670,007 | 48,899 |
Myopia
| Myopia | 17.78 million | 181,106 |
|---|---|---|
| High myopia | 2.67 million | 27,166 |
Uveitis (non-infectious)
| All | 77,974 | 20,738 |
|---|
Keratoconus
| All cases | 119,905 | 1,659 |
|---|
Corneal neuralgia
| All cases | 11,850 | 1,185 |
|---|
Inherited retinal disease
| Combined | 28,679 | 442 |
|---|
deu
53
24
Germany
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.23 million | 83,185 |
|---|---|---|
| Normal-tension | 416,626 | — |
Diabetic retinopathy
| NPDR | 765,400 | 187,828 |
|---|---|---|
| PDR | 408,526 | 38,228 |
Age-related macular degeneration
| Dry | 8.07 million | 677,928 |
|---|---|---|
| Wet | 896,970 | 65,235 |
Myopia
| Myopia | 25.32 million | 283,153 |
|---|---|---|
| High myopia | 3.8 million | 42,473 |
Uveitis (non-infectious)
| All | 111,082 | 29,543 |
|---|
Keratoconus
| All cases | 170,818 | 2,363 |
|---|
Corneal neuralgia
| All cases | 16,882 | 1,688 |
|---|
Inherited retinal disease
| Combined | 40,853 | 629 |
|---|
fra
51
27
France
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 895,744 | 61,717 |
|---|---|---|
| Normal-tension | 304,553 | — |
Diabetic retinopathy
| NPDR | 603,921 | 148,201 |
|---|---|---|
| PDR | 322,338 | 30,163 |
Age-related macular degeneration
| Dry | 5.9 million | 502,970 |
|---|---|---|
| Wet | 655,685 | 48,399 |
Myopia
| Myopia | 19.98 million | 246,169 |
|---|---|---|
| High myopia | 3 million | 36,925 |
Uveitis (non-infectious)
| All | 87,647 | 23,310 |
|---|
Keratoconus
| All cases | 134,780 | 1,865 |
|---|
Corneal neuralgia
| All cases | 13,320 | 1,332 |
|---|
Inherited retinal disease
| Combined | 32,234 | 495 |
|---|
gbr
50
22
United Kingdom
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 890,064 | 62,219 |
|---|---|---|
| Normal-tension | 302,622 | — |
Diabetic retinopathy
| NPDR | 628,879 | 154,326 |
|---|---|---|
| PDR | 335,660 | 31,409 |
Age-related macular degeneration
| Dry | 5.86 million | 507,068 |
|---|---|---|
| Wet | 651,527 | 48,793 |
Myopia
| Myopia | 20.81 million | 270,006 |
|---|---|---|
| High myopia | 3.12 million | 40,501 |
Uveitis (non-infectious)
| All | 91,269 | 24,274 |
|---|
Keratoconus
| All cases | 140,350 | 1,942 |
|---|
Corneal neuralgia
| All cases | 13,871 | 1,387 |
|---|
Inherited retinal disease
| Combined | 33,567 | 516 |
|---|
bra
35
67
Brazil
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 3.21 million | 183,610 |
|---|---|---|
| Normal-tension | 1.28 million | — |
Diabetic retinopathy
| NPDR | 777,998 | 420,580 |
|---|---|---|
| PDR | 844,753 | 79,047 |
Age-related macular degeneration
| Dry | 8.24 million | 1.39 million |
|---|---|---|
| Wet | 915,734 | 133,582 |
Myopia
| Myopia | 53.11 million | 845,945 |
|---|---|---|
| High myopia | 7.43 million | 126,892 |
Uveitis (non-infectious)
| All | 279,548 | 74,348 |
|---|
Keratoconus
| All cases | 552,703 | 7,647 |
|---|
Corneal neuralgia
| All cases | 42,485 | 4,248 |
|---|
Inherited retinal disease
| Combined | 102,812 | 1,580 |
|---|
mex
22
43
Mexico
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 1.45 million | 93,780 |
|---|---|---|
| Normal-tension | 578,912 | — |
Diabetic retinopathy
| NPDR | 481,302 | 260,189 |
|---|---|---|
| PDR | 522,600 | 48,902 |
Age-related macular degeneration
| Dry | 4.2 million | 709,038 |
|---|---|---|
| Wet | 466,865 | 68,228 |
Myopia
| Myopia | 32.85 million | 593,090 |
|---|---|---|
| High myopia | 4.6 million | 88,964 |
Uveitis (non-infectious)
| All | 172,940 | 45,995 |
|---|
Keratoconus
| All cases | 341,925 | 4,731 |
|---|
Corneal neuralgia
| All cases | 26,283 | 2,628 |
|---|
Inherited retinal disease
| Combined | 63,604 | 978 |
|---|
can
21
19
Canada
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 666,642 | 39,685 |
|---|---|---|
| Normal-tension | 213,325 | — |
Diabetic retinopathy
| NPDR | 1.38 million | 139,896 |
|---|---|---|
| PDR | 364,945 | 34,150 |
Age-related macular degeneration
| Dry | 2.68 million | 300,043 |
|---|---|---|
| Wet | 297,906 | 28,872 |
Myopia
| Myopia | 11.98 million | 152,911 |
|---|---|---|
| High myopia | 2 million | 22,937 |
Uveitis (non-infectious)
| All | 52,569 | 13,981 |
|---|
Keratoconus
| All cases | 80,839 | 1,118 |
|---|
Corneal neuralgia
| All cases | 7,989 | 799 |
|---|
Inherited retinal disease
| Combined | 19,334 | 298 |
|---|
usa
23
32
United States
Prevalence
New / yr
Modeled cases — prevalence · new / yr
Glaucoma
| Open-angle | 5.45 million | 328,071 |
|---|---|---|
| Normal-tension | 1.73 million | — |
Diabetic retinopathy
| NPDR | 11.98 million | 1.21 million |
|---|---|---|
| PDR | 3.16 million | 296,110 |
Age-related macular degeneration
| Dry | 21.92 million | 2.48 million |
|---|---|---|
| Wet | 2.44 million | 238,682 |
Myopia
| Myopia | 103.91 million | 1.41 million |
|---|---|---|
| High myopia | 17.32 million | 211,254 |
Uveitis (non-infectious)
| All | 455,828 | 121,231 |
|---|
Keratoconus
| All cases | 700,956 | 9,698 |
|---|
Corneal neuralgia
| All cases | 69,275 | 6,927 |
|---|
Inherited retinal disease
| Combined | 167,644 | 2,579 |
|---|
Modeled 2024 estimates across eight eye conditions, showing prevalence and annual new cases. Country counts use UN WPP 2024 population denominators and are modeled, not national registry totals.
Entrepreneurship for Better Vision
Where Clinical Purpose Meets Entrepreneurial Opportunity
You do not need to begin with an established eye-care practice to explore the opportunity. Netra Eye Institute is designed for qualified entrepreneurs and licensed professionals who share our commitment to patient safety, responsible integrative care, professional collaboration, disciplined operations, and long-term visual wellness.
Depending on state law, professional ownership requirements, scope-of-practice rules, and the final franchise structure, a non-clinician owner may operate through an approved management-services model while appropriately licensed professionals retain responsibility for clinical care.
Empower healthier vision
Be part of Netra and help transform lives through better vision.
Entrepreneurship for Better Vision
Why the Market Needs an Expanded Eye-Care Model
The need for vision care is substantial and growing:
- Approximately 7 million people in the United States live with vision impairment, including about 1 million people with blindness.
- About 93 million U.S. adults have been identified as being at high risk for serious vision loss.
- Aging, diabetes, vascular disease, chronic inflammation, environmental stress, and longer life expectancy are increasing the number of people who require long-term eye-health management.
- Many people with chronic eye disease remain functionally limited even while following conventional treatment plans.
- Interest in coordinated complementary and integrative healthcare has increased as patients seek whole-person support that works alongside established medical care.
Netra Eye Institute gives franchise owners a platform to address this growing demand through a structured, professionally governed, patient-centered model.
Entrepreneurship for Better Vision
What Is Netra Restoration Therapy?
Netra Restoration Therapy, or NRT, is a structured integrative eye-care framework developed by Netra Eye Institute. It combines individualized therapeutic planning with principles from Traditional Chinese Medicine, acupuncture, herbal and nutritional support, Ayurvedic ophthalmology, lifestyle guidance, and contemporary understanding of ocular physiology.
NRT is designed to support biological systems relevant to chronic ocular stress, including:
NRT is designed to support biological systems relevant to chronic ocular stress, including:
- Ocular blood-flow regulation and microcirculation
- Neurotrophic support and neuroretinal resilience
- Oxidative-stress regulation
- Inflammatory and cytokine balance
- Mitochondrial and metabolic support
- Iron-related lipid damage and ferroptosis pathways
- Autonomic and systemic contributors to ocular health
- Functional visual performance and patient quality of life
NRT does not replace conventional diagnosis or medically necessary treatment. Patients are expected to remain under the care of their ophthalmologist, optometrist, retinal specialist, glaucoma specialist, corneal specialist, or other appropriate physician.
business model
A Business Model Built Around Specialized Care
Focused Clinical Category
Rather than attempting to provide every form of general wellness care, Netra Eye Institute centers its brand, education, marketing, and operating systems on integrative support for ocular health and functional vision.
Structured Patient Programs
Patients receive an individualized evaluation and, when appropriate, a defined program with clinical goals, visit schedules, safety criteria, coordination expectations, and outcome tracking.
Direct-Pay Services
Many integrative services may be delivered on a direct-pay basis, eliminating dependence on insurance reimbursement. Actual billing practices, eligible services, HSA/FSA treatment, and professional-fee structures must follow applicable laws and the final operations model.
Relationship-Based Care
The model is designed to encourage clinically appropriate follow-up, reassessment, maintenance planning, education, and long-term patient relationships rather than isolated transactions.
Scalable Systems
Standardized training, technology, marketing, quality systems, and brand resources are intended to support replication across qualified markets while preserving individualized clinical judgment.
Process
Your Path to Ownership
01
Request Information
Submit the request form to receive the Franchise Information Report and introductory materials about the opportunity.
02
Conversation and Qualification
Meet the franchise development team to discuss your goals, market, ownership structure, and financial readiness.
03
Review the FDD
Receive the Franchise Disclosure Document and evaluate it carefully with independent franchise and healthcare counsel.
04
Due Diligence and Discovery Day
Complete your independent research, validate the model, and meet the leadership team in person.
05
Award, Training, and Opening
Sign the franchise agreement, complete territory and site work, finish training, and open your center.
POTENTIAL NETRA OWNERS
Designed for Purpose-Driven Owners
For Entrepreneurs and Investors
Build a differentiated healthcare business in a specialized field with a defined brand, structured operating system, clinical staffing framework, marketing resources, and ongoing franchise support.
For Licensed Professionals
Develop a focused practice in integrative eye care while receiving education, protocols, business
systems, peer support, and a pathway to ownership that would be difficult to build alone.
For Existing Practice Owners
Explore adding or converting space into a Netra Eye Institute center, subject to qualification, territory
availability, clinical compatibility, and franchise standards.
Franchise SupporT
The Netra Franchise Support Platform
Franchisees are not expected to build an integrative eye-care business alone. The Netra support platform is expected to include the following, as detailed in the FDD and operations manuals:
- Territory evaluation and market planning
- Site criteria and location review
- Clinic layout and design guidance
- Licensing and entity-structure guidance through approved professional resources
- Initial owner and team training
- NRT clinical education for eligible licensed professionals
- Recruitment profiles and hiring support
- Practice-management technology
- Brand standards and marketing assets
- Grand-opening planning
- Local patient-acquisition strategy
- Referral-development resources
- Clinical documentation standards
- Outcome-measurement frameworks
- Continuing education and protocol updates
- Operational coaching and performance review
- Compliance, safety, and quality support
FRanchise information
Is Netra Eye Institute the Right Opportunity for You?
We are seeking qualified owners who value patient safety, ethical marketing, professional collaboration, continuous learning, disciplined execution, and meaningful community impact.
Request the Franchise Information Report to learn more about:
Request the Franchise Information Report to learn more about:
- The Netra Eye Institute concept
- Netra Restoration Therapy
- Ideal owner profiles
- Clinical staffing requirements
- Training and support
- Territory-development strategy
- Estimated startup categories
- The franchise discovery process
- Next steps toward ownership
Partner with Netra to improve vision and change lives.
Legal Disclaimers: Please refer to Netra Eye Institute’s current Franchise Disclosure Document (“FDD”) for any authorized Financial Performance Representations. Actual financial results will vary. A franchisee’s revenue, expenses, profitability, and overall performance may be affected by factors including the local market, location, patient demand, service mix, pricing, operating costs, management capabilities, staffing, marketing expenditures, competition, and compliance with the Netra Eye Institute franchise system. No specific level of revenue, profit, or financial success is guaranteed. Any financial information presented applies only to the Netra Eye Institute franchise locations, operating periods, and reporting criteria specifically identified in Item 19 of the current FDD. Results from established locations may not reflect the results of a newly opened franchise. The information provided in this communication is for general informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, a franchise. A franchise may be offered only through the delivery of a current FDD in accordance with applicable law. Certain states require the FDD to be registered before a franchise may be offered or sold. This communication is not directed to residents of any jurisdiction where such an offer or communication would be unlawful. Netra Eye Institute will not offer or sell a franchise in any registration state until the applicable registration has been completed, or a valid exemption has been obtained, and the FDD has been delivered to the prospective franchisee in compliance with applicable law. To receive additional information about Netra Eye Institute franchise opportunities, prospective franchisees may complete the inquiry form and begin a preliminary conversation with our franchise development team.
This web site and the franchise sales information on this site do not constitute an offer to sell a franchise. The offer of a franchise can only be made through the delivery of a franchise disclosure document. Certain states require that we register the franchise disclosure document in those states. The communications on this web site are not directed by us to the residents of any of those states. Moreover, we will not offer or sell franchises in those states until we have registered the franchise (or obtained an applicable exemption from registration) and delivered the franchise disclosure document to the prospective franchisee in compliance with applicable law.
Netra Restoration Therapy is intended to complement, not replace, conventional eye care. Clinical services must be provided only by appropriately licensed professionals acting within their legal scopes of practice. Individual patient eligibility and outcomes vary. No result is guaranteed.
